An Evidence-Based Review On The Use Of Perampanel For The Treatment Of Focal-Onset Seizures In Pediatric Patients

Perampanel, a non-competitive AMPA receptor antagonist, is a once-daily oral antiepileptic drug approved for the treatment of focal seizures and primary generalized tonic–clonic seizures in children 12 years of age and over. We conducted a systematic review of the data on perampanel in children and...

Descripción completa

Detalles Bibliográficos
Autores principales: Dozières-Puyravel, Blandine, Auvin, Stéphane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767767/
https://www.ncbi.nlm.nih.gov/pubmed/31576134
http://dx.doi.org/10.2147/NDT.S178405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767767/
https://www.ncbi.nlm.nih.gov/pubmed/31576134
http://dx.doi.org/10.2147/NDT.S178405

Ejemplares similares